Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5466 - Levetiracetam offers a survival advantage in patients with epilepsy related to MGMT-unmethylated Glioblastoma


10 Sep 2017


Poster display session


Central Nervous System Malignancies


Leonardo Rojas


Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366


L. Rojas1, A. Ruiz-Patiño2, A.F. Cardona3, O. Arrieta4, Z. Zatarain-Barrón4

Author affiliations

  • 1 School Of Medicine, Pontificia Universidad Javeriana, 220246 - Bogotá/CO
  • 2 School Of Medicine, Hospital Universitario San Ignacio-Pontificia Universidad Javeriana, 110231 - Bogotá/CO
  • 3 Clinical Oncology, Foundation for Clinical and Applied Cancer Research FICMAC, Bogotá/CO
  • 4 Thoracic Oncology Unit And Laboratory Of Personalized Medicine, Instituto Nacional de Cancerologia - Mexico, 14080 - Ciudad de México/MX


Abstract 5466


Epilepsy is a common symptom in patients with glioblastoma (Gb). Levetiracetam (LEV), an antiepileptic drug (AED), enhances MGMT inhibition and reduces chemotherapy mediated neuronal toxicity, offering a theoretical benefit over other AEDs.


213 Hispanic patients were included. All patients underwent surgery (if feasible) followed by chemoradiation based on temozolomide. Type of AED was selected under treating physician discretion. Recorded variables included demographics, AED, dosage, MGMT status, performance status (PS) and type of surgical intervention. The relationship between overall survival (OS), AED and MGMT methylation status was explored.


Mean age was 53-yo (SD+/-14.7), 56.8% were male, 73% presented with epilepsy after diagnosis and 50.7% harbored methylated MGMT (metMGMT). 41% were treated with LEV, 26% were given another AED and 33% did not require any AED. AED indication was not associated with age (p = 0.087), PS (p = 0.78) anatomic tumor site (p = 0.34) or MGMT status (p = 0.98). Median OS was 25.8 months (95%CI 21.6-31.5), 27.9 months (95%CI 23.8-33.7) for those with metMGMT, and 11.83 months (95%CI 7.73-16.67) for non-metMGMT (p 


Retrospective analysis of this cohort suggests that LEV modifies OS in non-metMGMT Gb patients making it comparable to those with metMGMT. Further validation of this data in clinical trials is warranted.

Clinical trial identification

Legal entity responsible for the study

Leonardo Rojas




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.